PASG vs ILMN vs PACB vs NTLA vs CRSP vs KO

For growth investors, Intellia Therapeutics, Inc.

(NTLA) is the stronger pick with 16. 9% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). The Coca-Cola Company (KO) offers the better valuation at 26. 1x trailing P/E (24. 3x forward), making it the more compelling value choice. Analysts rate Illumina, Inc. (ILMN) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, The Coca-Cola Company (KO) is the cheapest at 26.

1x versus Illumina, Inc. at 29. 7x. On forward P/E, The Coca-Cola Company is actually cheaper at 24. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: The Coca-Cola Company wins at 2. 17x versus Illumina, Inc. 's 7. 33x.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

3%, compared to -98. 1% for Passage Bio, Inc. (PASG). Over 10 years, the gap is even starker: CRSP returned +283. 9% versus PASG's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Passage Bio, Inc. 's 3. 30β — meaning PASG is approximately -1512% more volatile than KO relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intellia Therapeutics, Inc.

(NTLA) is pulling ahead at 16. 9% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -70. 1% for Pacific Biosciences of California, Inc.. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — NTLA leads at 76. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, The Coca-Cola Company (KO) is the more undervalued stock at a PEG of 2. 17x versus Illumina, Inc. 's 7. 33x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, The Coca-Cola Company (KO) trades at 24. 3x forward P/E versus 31. 0x for Illumina, Inc. — 6. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTLA: 66. 8% to $26. 13.

In this comparison, KO (2.

6% yield) pays a dividend. PASG, ILMN, PACB, NTLA, CRSP do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Passage Bio, Inc. (PASG) carries a higher beta of 3. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +115. 0%, PASG: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PASG (Healthcare) and ILMN (Healthcare) and PACB (Healthcare) and NTLA (Healthcare) and CRSP (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PASG is a small-cap quality compounder stock; ILMN is a mid-cap quality compounder stock; PACB is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. KO pays a dividend while PASG, ILMN, PACB, NTLA, CRSP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.